Video Upload Options

References

1. Arnaud-López L, Fragoso R, Mantilla-Capacho J, Barros-Núñez P. Crouzon withacanthosis nigricans. Further delineation of the syndrome. Clin Genet. 2007Nov;72(5):405-10.
2. Brandling-Bennett HA, Morel KD. Epidermal nevi. Pediatr Clin North Am. 2010Oct;57(5):1177-98. doi: 10.1016/j.pcl.2010.07.004. Review.
3. Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau X,Chopin D, Thiery JP, Radvanyi F. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet. 1999 Sep;23(1):18-20.
4. Chen F, Degnin C, Laederich M, Horton WA, Hristova K. The A391E mutationenhances FGFR3 activation in the absence of ligand. Biochim Biophys Acta. 2011Aug;1808(8):2045-50. doi: 10.1016/j.bbamem.2011.04.007.
5. Chen F, Sarabipour S, Hristova K. Multiple consequences of a single amino acidpathogenic RTK mutation: the A391E mutation in FGFR3. PLoS One. 2013;8(2):e56521.doi: 10.1371/journal.pone.0056521.
6. Chen L, Deng CX. Roles of FGF signaling in skeletal development and humangenetic diseases. Front Biosci. 2005 May 1;10:1961-76. Review.
7. Desai SD, Vora R, Bharani S. Garcia-Hafner-Happle syndrome: A case report and review of a rare sub-type of epidermal nevus syndrome. J Pediatr Neurosci. 2014Jan;9(1):66-9. doi: 10.4103/1817-1745.131493.
8. Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growthfactor receptors. Cytokine Growth Factor Rev. 2005 Apr;16(2):139-49.
9. Hafner C, Di Martino E, Pitt E, Stempfl T, Tomlinson D, Hartmann A, LandthalerM, Knowles M, Vogt T. FGFR3 mutation affects cell growth, apoptosis andattachment in keratinocytes. Exp Cell Res. 2010 Jul 15;316(12):2008-16. doi:10.1016/j.yexcr.2010.04.021.
10. Hafner C, Hartmann A, van Oers JM, Stoehr R, Zwarthoff EC, Hofstaedter F,Landthaler M, Vogt T. FGFR3 mutations in seborrheic keratoses are already presentin flat lesions and associated with age and localization. Mod Pathol. 2007Aug;20(8):895-903.
11. Hafner C, Toll A, Fernández-Casado A, Earl J, Marqués M, Acquadro F,Méndez-Pertuz M, Urioste M, Malats N, Burns JE, Knowles MA, Cigudosa JC, HartmannA, Vogt T, Landthaler M, Pujol RM, Real FX. Multiple oncogenic mutations andclonal relationship in spatially distinct benign human epidermal tumors. ProcNatl Acad Sci U S A. 2010 Nov 30;107(48):20780-5. doi: 10.1073/pnas.1008365107.
12. Hafner C, van Oers JM, Vogt T, Landthaler M, Stoehr R, Blaszyk H, Hofstaedter F, Zwarthoff EC, Hartmann A. Mosaicism of activating FGFR3 mutations in humanskin causes epidermal nevi. J Clin Invest. 2006 Aug;116(8):2201-2207.
13. Hernández S, Toll A, Baselga E, Ribé A, Azua-Romeo J, Pujol RM, Real FX.Fibroblast growth factor receptor 3 mutations in epidermal nevi and associatedlow grade bladder tumors. J Invest Dermatol. 2007 Jul;127(7):1664-6.
14. Horton WA, Lunstrum GP. Fibroblast growth factor receptor 3 mutations inachondroplasia and related forms of dwarfism. Rev Endocr Metab Disord. 2002Dec;3(4):381-5. Review.
15. L'Hôte CG, Knowles MA. Cell responses to FGFR3 signalling: growth,differentiation and apoptosis. Exp Cell Res. 2005 Apr 1;304(2):417-31.
16. Lievens PM, Liboi E. The thanatophoric dysplasia type II mutation hamperscomplete maturation of fibroblast growth factor receptor 3 (FGFR3), whichactivates signal transducer and activator of transcription 1 (STAT1) from theendoplasmic reticulum. J Biol Chem. 2003 May 9;278(19):17344-9.
17. Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA,Shukla SA, Sanchez-Vega F, Hansel DE, Czerniak BA, Reuter VE, Su X, de SaCarvalho B, Chagas VS, Mungall KL, Sadeghi S, Pedamallu CS, Lu Y, Klimczak LJ,Zhang J, Choo C, Ojesina AI, Bullman S, Leraas KM, Lichtenberg TM, Wu CJ, SchultzN, Getz G, Meyerson M, Mills GB, McConkey DJ; TCGA Research Network, WeinsteinJN, Kwiatkowski DJ, Lerner SP. Comprehensive Molecular Characterization ofMuscle-Invasive Bladder Cancer. Cell. 2018 Aug 9;174(4):1033. doi:10.1016/j.cell.2018.07.036.
18. Rohmann E, Brunner HG, Kayserili H, Uyguner O, Nürnberg G, Lew ED, Dobbie A,Eswarakumar VP, Uzumcu A, Ulubil-Emeroglu M, Leroy JG, Li Y, Becker C, LehnerdtK, Cremers CW, Yüksel-Apak M, Nürnberg P, Kubisch C, Schlessinger J, van BokhovenH, Wollnik B. Mutations in different components of FGF signaling in LADDsyndrome. Nat Genet. 2006 Apr;38(4):414-7.Genet. 2006 Apr;38(4):495. Kubisch, Chriütian [corrected to Kubisch, Christian].
19. Toydemir RM, Brassington AE, Bayrak-Toydemir P, Krakowiak PA, Jorde LB, WhitbyFG, Longo N, Viskochil DH, Carey JC, Bamshad MJ. A novel mutation in FGFR3 causescamptodactyly, tall stature, and hearing loss (CATSHL) syndrome. Am J Hum Genet. 2006 Nov;79(5):935-41.
20. Vajo Z, Francomano CA, Wilkin DJ. The molecular and genetic basis offibroblast growth factor receptor 3 disorders: the achondroplasia family ofskeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome withacanthosis nigricans. Endocr Rev. 2000 Feb;21(1):23-39. Review.
21. van Rhijn BW, van Tilborg AA, Lurkin I, Bonaventure J, de Vries A, Thiery JP, van der Kwast TH, Zwarthoff EC, Radvanyi F. Novel fibroblast growth factorreceptor 3 (FGFR3) mutations in bladder cancer previously identified innon-lethal skeletal disorders. Eur J Hum Genet. 2002 Dec;10(12):819-24.
22. Zieger K, Dyrskjøt L, Wiuf C, Jensen JL, Andersen CL, Jensen KM, Ørntoft TF.Role of activating fibroblast growth factor receptor 3 mutations in thedevelopment of bladder tumors. Clin Cancer Res. 2005 Nov 1;11(21):7709-19.